All In Biotech

Drug Trial Radar · NCT00974974

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Aug 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 471 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

471

Actual

Start

Sep 2009

Primary completion

Jan 2011

Study completion Mar 2011

Sponsor

Lead sponsor
Impax Laboratories, LLCIndustry
Sponsor type
Industry
First posted
Sep 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.

Conditions

  • Parkinson's Disease

Interventions

  • IPX066Drug

    extended-release carbidopa-levodopa capsules

  • IR CD-LDDrug

    immediate-release carbidopa-levodopa tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of "Off" Time During Waking Hours at End of StudyTime frame: 22 weeks

Locations

73 sites in 8 countries. Site status is shown where the registry gives one.

  • Investigator 17

    Birmingham, Alabama

  • Investigator 49

    Phoenix, Arizona

  • Investigator 7

    Little Rock, Arkansas

  • Investigator 3

    La Jolla, California

  • Investigator 31

    Sunnyvale, California

  • Investigator 6

    Torrance, California

  • Investigator 51

    Aurora, Colorado

  • Investigator 10

    New Haven, Connecticut

  • Investigator 64

    Bradenton, Florida

  • Investigator 61

    Hollywood, Florida

  • Investigator 5

    Ocala, Florida

  • Investigator 15

    Port Charlotte, Florida

  • Investigator 8

    Port Charlotte, Florida

  • Investigator 4

    St. Petersburg, Florida

  • Investigator 46

    Augusta, Georgia

  • Investigator 38

    Boise, Idaho

  • Investigator 19

    Chicago, Illinois

  • Investigator 40

    Chicago, Illinois

  • Investigator 39

    Des Moines, Iowa

  • Investigator 29

    Kansas City, Kansas

  • Investigator 1

    Bingham Farms, Michigan

  • Investigator 21

    New Brunswick, New Jersey

  • Investigator 25

    Albany, New York

  • Investigator 8

    Commack, New York

  • Investigator 12

    New York, New York

  • Investigator 11

    Durham, North Carolina

  • Investigator 9

    Raleigh, North Carolina

  • Investigator 20

    Cincinnati, Ohio

  • Investigator 42

    Toledo, Ohio

  • Investigator 60

    Tulsa, Oklahoma

  • Investigator 14

    Charleston, South Carolina

  • Investigator 16

    Dallas, Texas

  • Investigator 13

    Houston, Texas

  • Investigator 65

    Tacoma, Washington

  • Investigator 2

    Milwaukee, Wisconsin

  • Investigator 24

    London, Ontario, Canada

  • Investigator 18

    Ottawa, Ontario, Canada

  • Investigator 26

    Québec, Quebec, Canada

  • Investigator 32

    Strasbourg, Alsace, France

  • Investigator 22

    Dijon, Bourgogne-Franche-Comté, France

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.